ACLX-004

N/A

Report date: 2025/09/04 16:17:10

Base Information

Drug NameACLX-004
Drug Alias NameACLX-004
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsInterleukin-3 receptor subunit alpha modulators
TargetsMyeloid cell surface antigen CD33Interleukin-3 receptor subunit alpha
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesArcellx Inc
China Registration ClassN/A

Develop Information

Active CompaniesArcellx Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A